[1] Pathak Y.,
Recent Developments in Nanoparticulate Drug Delivery Systems, Drug Delivery Nanoparticles Formulation and Characterization, 2016: 19-33 (2016).
[2] Lohcharoenkal W., Wang L., Chen Y.-C., Rojanasaku Y.,
Protein Nanoparticles as Drug Delivery Carriers for Cancer Therapy,
Biomed Research International, 2014: 1-12 (2014).
[3] Soppimath K.-S., Aminabhavi T.-J., Kulkarni A.-R., Rudzinsli W.-E.,
Biodegradable Polymeric Nanoparticles as Drug Delivery Devices,
Journal of Controlled Release, 70: 1-20 (2001).
[4] Salatin S.,
Jelvehgari M., Maleki-Dizaj S., Adibkia K.,
A Sight on Protein-Based Nanoparticles as Drug/Gene Delivery Systems, Therapeutic Delivery, 6: 1017-1029 (2015).
[5] Dobrovolskaia M.-A., Scott E.-M.,
Immunological Properties of Engineered Nanomaterials, Nature nanotechnology,
2: 469-478 (2007).
[6] Saif M.-W., Reardon J.,
Management of Oxaliplatin-Induced Peripheral Neuropathy,
Therapeutics and Clinical Risk Management,
1: 249–258 (2005).
[7] Peer D., Karp J., Hong S., Farokhzad O., Margalit R., Langer R.,
Nanocarriers as an Emerging Platform for Cancer Therapy,
Nature Nanotechnology,
2: 751-760 (2007).
[8] Rezaee F., Saeidifar M., Javaheri M., Sangpour P.,
Prolonged Release Evaluation of an Injectable Anticancer Drug using Human Serum Albumin Nanoparticle, Biomacromolecular Journal,
2: 118-125 (2016).
[9] نبی تیر معصومه؛ آقامیری سید فواد؛ طلایی خوزانی محمدرضا؛
بررسی آزمایشگاهی تأثیر پوشش دهی کیتوسان در کاهش تجمع نانولوله های کربنی به عنوان حامل داروی ضد سرطان کوئرستین،
نشریه شیمی و مهندسی شیمی ایران،
36: 93 تا 102 (1396).
[10] Ma P., Mumper R.-J.,
Paclitaxel Nano-Delivery Systems: A Comprehensive Review,
Journal of Nanomedicine & Nanotechnology, 18: 1000164 (2013).
[12] Nemati Kharat A., Tamaddoni Jahromi B., Mohammadifar E., Zareyi J.,
Synthesis of Cis-Diammine (1,1-cyclobutane dicarboxylate) Platinum(II),
Iranian Journal of Chemistry and Chemical Engineering,
36: 39-43 (2017).
[14] Janeway Jr., Charles A., Travers P., Walport M., "
The Structure of a Typical Antibody Molecule", Garland Science, New York (2001).
[15] Wong H.-M., Wang J.-J., Wang C.-H.,
In Vitro Sustained Release of Human Immunoglobulin G from Biodegradable Microspheres,
Industrial & Engineering Chemistry Research. 40: 933-948 (2001).
[16] Wang J., Chua K.-M., Wang C.-H.,
Stabilization and Encapsulation of Human Immunoglobulin G Into Biodegradable Microspheres, Journal of Colloid And Interface Science, 271: 92-101 (2004).
[17] Marquette S., Peerboom C., Yates A., Denis L., Langer I., Amighi K., Goole J.,
Stability Study of Full-Length Antibody (anti-TNF alpha) Loaded PLGA Microspheres,
International Journal of Pharmaceutics, 470: 41-50 (2014).
[18] Elzoghby A.-O., Wael M.-S., Nazik A.-E.,
Albumin-Based Nanoparticles as Potential Controlled Release Drug Delivery Systems, Journal of Controlled Release, 157: 168-182 (2012).
[21] Langer K., Anhorn M., Steinhauser I., Dreis S., Celebi D., Schrickel N., Faust S., Vogel V.,
Human Serum Albumin (HSA) Nanoparticles: Reproducibility of Preparation Process and Kinetics of Enzymatic Degradation,
International Journal of Pharmaceutics, 347: 109-117 (2008).
[22] Jahanban.-E A., Dastmalchi S., Davaran S.,
A simple Improved Desolvation Method for the Rapid Preparation of Albumin Nanoparticles, International Journal of Biological Macromolecules,
91: 703-709 (2016).
[23] Guven A., Rusakova I.-A., Lewis M.-T., Wilson L.-J.,
Cisplatin@ US-Tube Carbon Nanocapsules for Enhanced Chemotherapeutic Delivery,
Biomaterials, 33: 1455-1461 (2012).
[24]Singhvi G., Singh M.,
In-vitro Drug Release Characterization Models, International Journal of Pharmaceutical Sciences and Research, 2: 77-84 (2011).
[26] Suvakanta D., Murthy P.-N., Nath L., Chowdhury P.,
Kinetic Modeling on Drug Release from Controlled Drug Delivery Systems, Acta Poloniae Pharmaceutica,
67: 217-23 (2010).
[27] Kirubha S.-P., M. Anburajan.,
Spectrometric Techniques for Diagnosis of Breast Cancer,
International Conference on Computer Communication and Informatics, 2: 1-4 (2012).
